Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study Finds a Link Between Fatty Acid Ratios and Breast Cancer

June 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--A study of European women suffering from breast cancer has raised the intriguing possibility that the ratio of omega-3 to omega-6 polyunsaturated fatty acids (PUFA) may provide a way to predict an increased risk of the malignancy.

WASHINGTON--A study of European women suffering from breast cancerhas raised the intriguing possibility that the ratio of omega-3to omega-6 polyunsaturated fatty acids (PUFA) may provide a wayto predict an increased risk of the malignancy.

"We have looked at the balance between the two," saidepidemiologist Neil Simonsen, PhD, of the University of NorthCarolina at Chapel Hill, School of Public Health. "When wedo that, the ratio of omega-3 to omega-6 appears to be important.The higher the ratio, the more protective."

Therefore, he said, the balance between the two forms of PUFAsmay prove more relevant to the etiology of breast cancer thanthe absolute intake of a single fatty acid class.

Dr. Simonsen described the findings at Experimental Biology 96,an annual meeting of biological and biomedical researchers.

The PUFA ratio picture emerged from an analysis Dr. Simonsen conductedwith colleagues at the University of North Carolina and in Europe,which failed to confirm laboratory suggestions that a diet highin omega-6 fatty acids enhances mammary tumor activity.

The omega-6 fatty acids constitute the most common PUFA groupand include fats from corn oil and other vegetable sources. Thesecond PUFA family, omega-3, is found in fish, primarily oceanfishes.

Dr. Simonsen and his colleagues used data from EURAMIC (EuropeanStudy of Antioxidants, Myocardial Infarction, and Breast Cancer),a case-control investigation involving men and women. As partof the EURAMIC trial, investigators needle-biopsied adipose tissuefrom participants' buttocks to determine the antioxidant and fattyacid content.

Women From Five Nations

The researchers analyzed data from 698 women from five nations--Germany,Switzerland, Spain, The Netherlands, and Northern Ireland. Thesample included 291 women with primary breast cancer and 407 controlsselected from the same hospital catchment areas as the patients.

All were postmenopausal, with no major change in their weight,diet, or antioxidant use in the previous year. Other risk factorsfor breast cancer were considered in the analysis, including age,postmenopausal estrogen therapy, oral-contraceptive use, currentalcohol consumption, smoking status, parity, and age at menarcheand menopause.

Overall, the data indicated a statistically significant associationbetween higher concentrations of omega-6 in adipose cells andbreast cancer, but this was due to a high correlation found inone country--Spain. "If you exclude the patients from theSpanish center, the association goes away," he said.

An explanation may lie in the Spanish diet, which is high in oliveoil. Several studies have reported a protective association witholive oil consumption in southern European populations. The researchersfound that the Spanish women who had high levels of omega-6 alsohad low levels of oleic acid, a monounsat-urated fat dominantin olive oil--and vice versa.

The results for the Spanish women could indicate a reduction insome protective mechanism that eating olive oil provides, ratherthan a linkage between omega-6 and breast cancer, he said.

"It's hard to say that at the Spanish center that the findingis due to omega-6 and not to olive oil," Dr. Simonsen said."You see the same pattern whether you look at increasinglevels of polyunsat-urates or decreasing levels of oleic acid."

Right now, he said, "it's hard to make a smoking-gun recommendationfor clinicians." The new data may be making a further casefor olive oil, he said, "but we don't know if it's oliveoil or something else in that Mediterranean diet."

The study's most intriguing finding, in his view, is the possibilitythat the key factor in determining risk lies in the ratio of omega-3to omega-6.

The researchers are now in the midst of a more in-depth analysisof the omega-3/omega-6 ratio and other differences between thetwo PUFAs. They see this as more likely to provide illuminatinganswers than focusing on one fatty acid at a time. They also hopeto gain greater insights into the role of oleic acid and breastcancer.

"The real take-home message is that focusing in on just oneindividual type of fatty acid may not be the way to go,"Dr. Simonsen said. "We've got to look at the relationshipsbetween the different types."

Articles in this issue

Psychosocial Oncology May Benefit From System Reform
Know Your Partners, Know Your Goals in Joint Ventures Between Hospitals and Universities
Managed Care Reform: Wait Until Next Year for House, Senate
Converting Quality of Life Data to 'Q' Scores Allows Comparisons
Shorter Paclitaxel Infusions Add to Neuropathy Risk
Breast Cancer Mortality Rates Down

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 4th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 4th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 4th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
September 4th 2025
Podcast

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
September 4th 2025
Article

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
September 4th 2025
Article
Related Content

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 4th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 4th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 4th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
September 4th 2025
Podcast

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
September 4th 2025
Article

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
September 4th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.